Secondary prevention with clopidogrel in patients with clinically manifested atherothrombosis in daily primary care;Sekundärprophylaxe mit clopidogrel bei patienten mit klinisch manifester atherothrombose in der täglichen hausärztlichen praxis

Perfusion

Volumn 17, Issue 5, 2004, Pages 178-184

  Silber, Sigmund ^a   Mahn, Matthias ^b  

^a Kardiologische Praxis und Praxisklinik   (Germany)

^b Division Henning   (Germany)

Author keywords

Aspirin; Atherothrombosis; Cerebrovascular disease; Clopidogrel; Co morbidity; Coronary artery disease; Peripheral arterial occlusive disease; Pharmacoepidemiology; Primary care; Risk factors; Secondary prevention

Indexed keywords

EID: 24944507719     PISSN: 09350020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hennekens CH. Increasing burden of cardiovascular disease: Current knowledge and future directions for research on risk factors. Circulation 1998;97:1095-1102
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-2753
3. Leys D. Atherothrombosis: a major health burden. Cerebrovasc Dis 2001;11(Suppl 2):1-4
4. Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov R, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham I. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
5. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-1900
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-2572
7. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy - Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-156
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86
10. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324
11. Pittrow D, Lange S, Trampisch H, Darius H, Tepohl G, Allenberg J, v. Stritzky B, Haberl R, Diehm C. The German Trial on Ankle Brachial Index (getABI): high prevalence and evidence for antiplatelet undertreatment of peripheral arterial disease in primary care. Int J Clin Pharmacol Ther 2003;41:445(P427)
12. Smith SC, Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-1579
13. Silber S, Albertson P, Aviles FF, et al. European guidelines for percutaneous coronary interventions (PCI). Eur Heart J 2004 (in press)
14. DGN KLd. Leitlinien der Deutschen Gesellschaft für Neurologie, 1. Aufl. Essen, 2002
15. Deutsche Gesellschaft für Angiologie, Deutsche Gesellschaft für Gefäßmedizin. Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit der Becken-Beinarterien. VASA;30:1-19
16. Gibbons R, Abrams J, Chatterjee K, Daley J, Deedwania P, Douglas J, Ferguson T, Fihn S, Fraker T, Gardin J, O'Rourke R, Pasternak R, Williams S. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-168
17. Hamm CW. Leitlinien: Akutes Koronarsyndrom (ACS). Z Kardiol 2004;93:72-90
18. Bhatt D, Topol E. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:15-28
19. Knight CJ. Antiplatelet treatment in stable coronary artery disease. Heart 2003;89:1273-1278
20. Bhatt D, Marso S, Hirsch A, Ringleb P, Hacke W, Topol E. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-628
21. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-368
22. Steinhubl SR, Berger PB, Mann III JT, Fry ETA, DeLago A, Wilmer C, Topol EJ, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420
23. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
24. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KAA, on Behalf of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972
25. Caro J, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus aspirin in patients at risk of ischaemic events. Am J Med 1999;107:568-572
26. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339
27. Diehm C, Schuster A, Allenberg H, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch H. High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis 2004;172:95-105
28. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE Study. Arch Intern Med 2003;163:1145-1153
29. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904
30. Frost PH, Davis BR, Burlando AJ, David Curb J, Guthrie GP, Jr, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J. Coronary heart disease risk factors in men and women aged 60 years and older: Findings from the Systolic Hypertension in the Elderly Program. Circulation 1996;94:26-34
31. Tepohl G, Diehm C, Lange S, Pittrow D, et al. Jeder fünfte ältere Patient in der Praxis leidet an AVK. Cardiovasc 2003;7:16-20
32. Wittchen HU, Krause P, Höfler M, Pfister H, Ritz H, Göke B, Lehnert H, Tschöpe D, Kirch W, Pittrow D, Sharma A, Bramlage P, Küpper B, Unger T. Arterielle Hypertonie, Diabetes mellitus und assoziierte Erkrankungen in der Allgemeinarztpraxis. Fortschr Med 2003;Suppl.I:19-27
33. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, Taubert KA. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: A scientific statement for healthcare professionals from the stroke council and the council on clinical cardiology of the American Heart Association/American Stroke Association. Circulation 2003;108:1278-1290
34. Vernino S, Brown RD, Jr, Sejvar JJ, Sicks JD, Petty GW, O'Fallon WM. Cause-specific mortality after first cerebral infarction: A population-based study. Stroke 2003;34:1828-1832
35. Trampisch HJ, Windeler J. Medizinische Statistik. 1. Aufl. Berlin: Springer; 1997:25-28
36. Novo S. Classification, epidemiology, risk factors, and natural history of peripheral arterial disease. Diabetes Obes Metab 2002;4 Suppl 2:S1-S6.
37. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P, Tunstall-Pedoe H. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. A statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108:2543-2549